The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma
N Giannakoulas, I Ntanasis-Stathopoulos… - International Journal of …, 2021 - mdpi.com
The development and effectiveness of novel therapies in multiple myeloma have been
established in large clinical trials. However, multiple myeloma remains an incurable …
established in large clinical trials. However, multiple myeloma remains an incurable …
Myeloma bone disease: a comprehensive review
SKR Mukkamalla, D Malipeddi - International journal of molecular …, 2021 - mdpi.com
Multiple myeloma (MM) is a neoplastic clonal proliferation of plasma cells in the bone
marrow microenvironment, characterized by overproduction of heavy-and light-chain …
marrow microenvironment, characterized by overproduction of heavy-and light-chain …
Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression
P Maiso, P Mogollón, EM Ocio, M Garayoa - Cancers, 2021 - mdpi.com
Simple Summary Multiple myeloma is a cancer of immunoglobulin-secreting cells that
accumulate in the bone marrow. Mesenchymal stromal cells are important components of …
accumulate in the bone marrow. Mesenchymal stromal cells are important components of …
Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma
Z Liu, F Mi, M Han, M Tian, L Deng… - Clinical & …, 2021 - academic.oup.com
High expression of the inhibitory receptor programmed cell death ligand 1 (PD-L1) on tumor
cells and tumor stromal cells have been found to play a key role in tumor immune evasion in …
cells and tumor stromal cells have been found to play a key role in tumor immune evasion in …
Bone marrow microenvironment interplay and current clinical practice in multiple myeloma: A review of the Balkan myeloma study group
J Bila, E Katodritou, M Guenova, S Basic-Kinda… - Journal of clinical …, 2021 - mdpi.com
The course of multiple myeloma (MM) is influenced by a variety of factors, including the
specificity of the tumour microenvironment (TME). The aim of this review is to provide insight …
specificity of the tumour microenvironment (TME). The aim of this review is to provide insight …
Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response …
IV Kostopoulos, E Eleutherakis-Papaiakovou… - Cancers, 2021 - mdpi.com
Simple Summary Autologous stem cell transplantation (ASCT) remains the standard of care
for transplant-eligible newly diagnosed Multiple Myeloma (NDMM) patients. However …
for transplant-eligible newly diagnosed Multiple Myeloma (NDMM) patients. However …
[HTML][HTML] Are the derived indexes of peripheral whole blood cell counts (NLR, PLR, LMR/MLR) clinically significant prognostic biomarkers in multiple myeloma? A …
X Zhang, J Duan, Z Wen, H Xiong, X Chen, Y Liu… - Frontiers in …, 2021 - frontiersin.org
Background Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole
blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for …
blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for …
[HTML][HTML] Multiple Myeloma Treatment
E Tekin, Ö Çağlar, E Özyılmaz, O Erbaş - Journal of Experimental and …, 2021 - jebms.org
Multiple myeloma (MM) is a cancer that begins in the plasma cells (PC) and progresses to
the bone marrow. It is a recurring disease, as no definitive solution can be found despite the …
the bone marrow. It is a recurring disease, as no definitive solution can be found despite the …
Tellurium compound provides pro-apoptotic signaling in drug resistant multiple myeloma
E Zigman-Hoffman, B Sredni, B Meilik… - Leukemia & …, 2021 - Taylor & Francis
Multiple Myeloma, effectively treated by chemotherapeutic drugs, relapses due to drug
resistance. We tested here the capacity of mesenchymal stromal cells, from the bone marrow …
resistance. We tested here the capacity of mesenchymal stromal cells, from the bone marrow …
Bivalent antibody directed against NKG2D and tumor associated antigens
(57) ABSTRACT A polypeptide is disclosed that binds tumor-associated anti gens (TAA) on
the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the …
the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the …